Condensed Consolidated Statements of Stockholders’ Equity (Deficit) (Unaudited) - USD ($)	Total	Common stock	Additional paid-in capital	Accumulated other comprehensive loss	Accumulated deficit
Beginning balance (in shares) at Dec. 31, 2023		8,331,161
Beginning balance at Dec. 31, 2023	$ (5,047,640)	$ 833	$ 166,548,454	$ (360,896)	$ (171,236,031)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	627,700		627,700
Issuance of common stock, net of issuance costs (in shares)		50,664
Issuance of common stock, net of issuance costs	215,113	$ 5	215,108
Net (loss) income	(6,755,356)				(6,755,356)
Foreign currency translation adjustments	(39,227)			(39,227)
Ending balance (in shares) at Mar. 31, 2024		8,381,825
Ending balance at Mar. 31, 2024	(10,999,410)	$ 838	167,391,262	(400,123)	(177,991,387)
Beginning balance (in shares) at Dec. 31, 2023		8,331,161
Beginning balance at Dec. 31, 2023	(5,047,640)	$ 833	166,548,454	(360,896)	(171,236,031)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	1,452,799
Foreign currency translation adjustments	(1,729)
Ending balance (in shares) at Sep. 30, 2024		8,546,364
Ending balance at Sep. 30, 2024	(1,484,483)	$ 854	168,660,520	(362,625)	(169,783,232)
Beginning balance (in shares) at Mar. 31, 2024		8,381,825
Beginning balance at Mar. 31, 2024	(10,999,410)	$ 838	167,391,262	(400,123)	(177,991,387)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	562,719		562,719
Issuance of common stock, net of issuance costs (in shares)		42,583
Issuance of common stock, net of issuance costs	182,978	$ 4	182,974
Reverse stock split adjustment (in shares)		121,953
Reverse stock split adjustment	0	$ 12	(12)
Net (loss) income	12,910,656				12,910,656
Foreign currency translation adjustments	14,563			14,563
Ending balance (in shares) at Jun. 30, 2024		8,546,361
Ending balance at Jun. 30, 2024	2,671,506	$ 854	168,136,943	(385,560)	(165,080,731)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	523,577		523,577
Reverse stock split adjustment (in shares)		3
Net (loss) income	(4,702,501)				(4,702,501)
Foreign currency translation adjustments	22,935			22,935
Ending balance (in shares) at Sep. 30, 2024		8,546,364
Ending balance at Sep. 30, 2024	$ (1,484,483)	$ 854	168,660,520	(362,625)	(169,783,232)
Beginning balance (in shares) at Dec. 31, 2024	8,700,386	8,700,386
Beginning balance at Dec. 31, 2024	$ (6,012,089)	$ 870	169,705,480	(428,809)	(175,289,630)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	377,357		377,357
Issuance of common stock, net of issuance costs (in shares)		150,000
Issuance of common stock, net of issuance costs	436,248	$ 15	436,233
Net (loss) income	(4,378,307)				(4,378,307)
Foreign currency translation adjustments	13,090			13,090
Ending balance (in shares) at Mar. 31, 2025		8,850,386
Ending balance at Mar. 31, 2025	$ (9,563,701)	$ 885	170,519,070	(415,719)	(179,667,937)
Beginning balance (in shares) at Dec. 31, 2024	8,700,386	8,700,386
Beginning balance at Dec. 31, 2024	$ (6,012,089)	$ 870	169,705,480	(428,809)	(175,289,630)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(11,957,556)
Foreign currency translation adjustments	$ 32,843
Ending balance (in shares) at Sep. 30, 2025	13,929,502	13,929,502
Ending balance at Sep. 30, 2025	$ 2,857,903	$ 1,393	190,499,662	(395,966)	(187,247,186)
Beginning balance (in shares) at Mar. 31, 2025		8,850,386
Beginning balance at Mar. 31, 2025	(9,563,701)	$ 885	170,519,070	(415,719)	(179,667,937)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	359,018		359,018
Issuance of common stock, net of issuance costs (in shares)		180,000
Issuance of common stock, net of issuance costs	475,013	$ 18	474,995
Net (loss) income	(4,016,483)				(4,016,483)
Foreign currency translation adjustments	12,893			12,893
Ending balance (in shares) at Jun. 30, 2025		9,030,386
Ending balance at Jun. 30, 2025	(12,733,260)	$ 903	171,353,083	(402,826)	(183,684,420)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	403,027		403,027
Issuance of common stock, net of issuance costs (in shares)		4,899,116
Issuance of common stock, net of issuance costs	18,744,042	$ 490	18,743,552
Net (loss) income	(3,562,766)				(3,562,766)
Foreign currency translation adjustments	$ 6,860			6,860
Ending balance (in shares) at Sep. 30, 2025	13,929,502	13,929,502
Ending balance at Sep. 30, 2025	$ 2,857,903	$ 1,393	$ 190,499,662	$ (395,966)	$ (187,247,186)

Dare Bioscience, Inc. 10-Q